Asgard Therapeutics
Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to trigger immune responses based on the biology of professional antigen-presenting cells. Backed by leading investors, Asgard aims to build a pipeline of personalized cancer immunotherapies.